REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 204 filers reported holding REATA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.50 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $22,024,584 | +17.1% | 216,012 | +4.4% | 0.01% | 0.0% |
| Q1 2023 | $18,804,529 | +140.3% | 206,825 | +0.4% | 0.01% | +100.0% |
| Q4 2022 | $7,826,700 | +53.7% | 206,020 | +1.7% | 0.00% | +50.0% |
| Q3 2022 | $5,091,000 | -14.1% | 202,559 | +3.9% | 0.00% | 0.0% |
| Q2 2022 | $5,927,000 | -9.6% | 195,010 | -2.6% | 0.00% | 0.0% |
| Q1 2022 | $6,558,000 | +28.4% | 200,153 | +3.4% | 0.00% | 0.0% |
| Q4 2021 | $5,106,000 | -73.4% | 193,627 | +1.6% | 0.00% | -66.7% |
| Q3 2021 | $19,173,000 | -27.0% | 190,564 | +2.7% | 0.01% | -33.3% |
| Q2 2021 | $26,273,000 | +108.4% | 185,635 | +46.8% | 0.01% | +80.0% |
| Q1 2021 | $12,608,000 | -22.0% | 126,450 | -3.3% | 0.01% | -16.7% |
| Q4 2020 | $16,165,000 | +40.2% | 130,758 | +10.5% | 0.01% | +20.0% |
| Q3 2020 | $11,534,000 | -43.4% | 118,386 | -9.4% | 0.01% | -50.0% |
| Q2 2020 | $20,388,000 | -13.4% | 130,671 | -19.9% | 0.01% | -28.6% |
| Q1 2020 | $23,545,000 | -23.3% | 163,119 | +8.6% | 0.01% | -12.5% |
| Q4 2019 | $30,694,000 | +186.9% | 150,141 | +12.7% | 0.02% | +166.7% |
| Q3 2019 | $10,697,000 | +11.9% | 133,228 | +31.5% | 0.01% | 0.0% |
| Q2 2019 | $9,561,000 | +16.1% | 101,326 | +5.2% | 0.01% | +20.0% |
| Q1 2019 | $8,232,000 | +60.5% | 96,310 | +5.4% | 0.01% | +25.0% |
| Q4 2018 | $5,128,000 | -31.6% | 91,393 | -0.3% | 0.00% | -20.0% |
| Q3 2018 | $7,497,000 | +203.2% | 91,689 | +29.7% | 0.01% | +150.0% |
| Q2 2018 | $2,473,000 | +143.6% | 70,702 | +43.0% | 0.00% | +100.0% |
| Q1 2018 | $1,015,000 | -25.4% | 49,458 | +2.9% | 0.00% | 0.0% |
| Q4 2017 | $1,361,000 | -12.2% | 48,054 | -3.6% | 0.00% | 0.0% |
| Q3 2017 | $1,550,000 | +80.0% | 49,828 | +83.2% | 0.00% | 0.0% |
| Q2 2017 | $861,000 | +102.1% | 27,200 | +44.7% | 0.00% | – |
| Q1 2017 | $426,000 | +3.6% | 18,800 | 0.0% | 0.00% | – |
| Q4 2016 | $411,000 | +71.2% | 18,800 | +106.6% | 0.00% | – |
| Q3 2016 | $240,000 | – | 9,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |